Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Nivolumab

5

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

3
Last update : 05/02/2018
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Avelumab
1
Durvalumab
3
Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx
5
Lambrolizumab
4
PD-1/PD-L1-inhibitors or blocking agents/drugs
5
Pembrolizumab
5

Publications

Severe acute interstitial lung disease after nivolumab in three non-small cell lung cancer patients with imaging findings of airway obstruction adjacent to lung tumors.
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2017 Dec;23;826-829 2017 Dec
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.
The European respiratory journal 2017 Aug;50; 2017 Aug
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
The New England journal of medicine 2015 May 21;372;2006-17 2015 May 21
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
The Lancet. Oncology 2015 Mar;16;257-65 2015 Mar
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Jun 20;33;2004-12 2015 Jun 20
Checkpoint blocking antibodies in cancer immunotherapy.
FEBS letters 2014 Jan 21;588;368-76 2014 Jan 21
Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2013;; 2013
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
The New England journal of medicine 2012 Jun 28;366;2443-54 2012 Jun 28

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies